Dutch Patients Wait Years for Approved Cancer Drugs

The Netherlands is stuck waiting nearly two years for nearly 50 cutting-edge cancer treatments—already approved in Germany—that could save lives, all because of cost negotiations. While Germany moves swiftly to approve and price these therapies, Dutch regulators are taking a cautious, value-driven approach, even though it’s delaying life-changing care. Two treatments born from Dutch hospitals are still on hold, despite promising to improve quality of life. Critics argue the delays aren’t cutting costs much and may be costing patients their time—and possibly their lives. The system aims for value, but the human cost is still being measured. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/0f50bf5c69d72302